Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 30, 2014Journal of Clinical OncologyOpen Access

Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

View Full Paper
Ask AI
Bookmark
Share

Authors

CKChristopher G. KanakryNational Institutes of HealthPOPaul V. O’DonnellMassachusetts General HospitalTFTerry FurlongFred Hutch Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kanakry et al. (2014) studied this question.

synapsesocial.com/papers/6a1bc24eb33628da419ccf2fhttps://doi.org/10.1200/jco.2013.54.0625
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials1998 · 121 citations
  2. 2Revised Response Criteria for Malignant Lymphoma2007 · 4,467 citations
  3. 3T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation2013 · 503 citations
  4. 4Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS2004 · 421 citations